19 October-30 November 2020
The 51st Union World Conference On Lung Health
REGISTER NOW

Event

Channel 6
OA-16-TB Xpert in low- and middle-income countries: ensuring quality and quantity
event_note
Loading...
query_builder 12:30 - 13:50 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Oral Abstract session
mic English
OA-16-TB Xpert in low- and middle-income countries: ensuring quality and quantity
*Please scroll down for more information*


12:30 - 12:35: Introduction


12:35 - 12:43: OA-16-598-22-Phased scale-up of external quality assurance for GeneXpert MTB/RIF testing under national TB elimination programme , India India's TB programme has rapidly scaled-up GeneXpert MTB/Rif testing, almost doubling the sites (628 to 1180), and testing has increased by five times (578173-2407211) from 2016 to 2018. To ensure a quality testing process, it strategically implemented External Quality Assurance (EQA) in a phased manner to monitor the quality of testing.

K Reena

12:43 - 12:51: OA-16-599-22-South Africa’s Xpert MTB/RIF Ultra external quality assurance experience: a need for good laboratory practice to minimise contamination South Africa's experience using external quality assurance in detecting contamination, due to Xpert® MTB/RIF Ultra’s increased sensitivity, and the need for improved good laboratory practice. A notable increase in the number of discordant results was analysed to advise on programme training needs and procedures to be reviewed for minimising contamination in routine settings.

Puleng Marokane

12:51 - 12:59: OA-16-600-22-Mentoring TB labs for improving and sustaining quality management system implementation and ISO 15189 accreditation: experiences from India The abstract focuses on experiences from India for improving and sustaining quality management system (QMS) implementation and ISO 15189 accreditation at 11 tuberculosis laboratories through mentoring support over the last three years

Tarak Shah

12:59 - 13:07: OA-16-601-22-A pilot study on the implementation of proficiency testing dried tube specimen production at a national public health laboratory: National Tuberculosis Laboratory, Kenya The external quality assurance panels enable facilities to identify diagnostic gas on time to enable continuity of quality services.
The Kenya National Tuberculosis Reference Laboratory demonstrated competency for panel production and managing the pilots, including corrective actions. These was made possible by mentorship from the US CDC, Atlanta, and the SRL, Uganda.

Solomon Bundi

13:07 - 13:15: OA-16-602-22-Role of GeneXpert technology in early detection of rifampicin-resistant TB in Afghanistan Elimination of tuberculosis (TB) is a major health priority for Afghanistan. Multidrug-resistant tuberculosis (MDR-TB) poses enormous challenges to health systems due to the complexity of diagnoses and treatment. For better diagnostic of presumptive MDR-TB patients, new bacteriologic-confirmed patients and extra-pulmonary TB, the national TB programme installed 49 GeneXpert machines.

Del Aqa Safi

13:15 - 13:23: OA-16-603-22-Overcoming barriers to GeneXpert optimisation in Nigeria: an analysis using the access concept GeneXpert optimisation is key to improving tuberculosis (TB) diagnosis, including rifampicin-resistant TB. However, Nigeria is yet to achieve the optimisation goal. This qualitative case-based study analyses barriers to effective GeneXpert optimisation using the ‘access concept’ and proposes proven health system and community strategies to surmount them.

Ogoamaka Chukwuogo

13:23 - 13:31: OA-16-604-22-The use of Xpert MTB/RIF in mobile vans: experience from Namibia A Namibian experience of using Xpert MTB/RIF instruments in mobile vans to demonstrate the feasiblility of use of these instruments in field-based screening activities. This demonstration proves that Gene X-pert can be utilised effectively outside routine laboratory settings to screen and diagnose drug-resistant tuberculosis (TB) in order to combat TB transmission.

Anita Beukes

13:31 - 13:50: Q&A


Loading...
Processing. Please wait.
Loading...